NASDAQ:KNTE

Kinnate Biopharma - KNTE Price Target & Analyst Ratings

$11.65

+0.21 (+1.84%)

(As of 10/4/2022 11:47 AM ET)

Add

Compare

Today's Range: $11.60
▼
$11.91
50-Day Range: $9.86
▼
$15.76
52-Week Range: $7.18
▼
$26.05

Volume: 1,121 shs
Average Volume: 151,357 shs
Market Capitalization: $514.35 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $32.00

Kinnate Biopharma Consensus Rating and Price Target (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Buy
Based on 5 Analyst Ratings

Consensus Analyst Price Target

$32.00
174.68% Upside

High Prediction	$35.00
Average Prediction	$32.00
Low Prediction	$29.00

Type	Current 10/4/21 to 10/4/22	1 Month Ago 9/4/21 to 9/4/22	3 Months Ago 7/6/21 to 7/6/22	1 Year Ago 10/4/20 to 10/4/21
Consensus Rating	Buy	Buy	Buy	Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	5 Buy rating(s)	6 Buy rating(s)	6 Buy rating(s)	7 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$32.00	$36.17	$36.80	$47.67
Predicted Upside	174.68% Upside	170.71% Upside	170.11% Upside	44.39% Upside

Get Kinnate Biopharma Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for KNTE and its competitors with MarketBeat's FREE daily newsletter.

KNTE Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

KNTE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Kinnate Biopharma Stock vs. The Competition

Type	Kinnate Biopharma	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.68	2.49
Consensus Rating	Buy	Buy	Hold
Predicted Upside	179.72% Upside	1,074.32% Upside	31.91% Upside
News Sentiment Rating	Positive News	Positive News	Neutral News
MarketBeat Community Rating	Outperform Votes 11 64.71% Underperform Votes 6 35.29%	Avg. Outperform Votes 166 66.67% Avg. Underperform Votes 83 33.33%	Avg. Outperform Votes 852 68.38% Avg. Underperform Votes 394 31.62%

Historical Target Prices and Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/14/2022	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform	$33.00	+166.77%
7/28/2022	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$33.00	+174.09%
5/24/2022	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy	$44.00 ➝ $29.00	+178.85%
5/18/2022	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight	$52.00 ➝ $30.00	+201.20%
2/11/2022	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Benjamin Burnett Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$35.00	+248.95%
9/27/2021	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$46.00	+102.91%
7/13/2021	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Lugo Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
12/28/2020	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Berens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$52.00	+36.84%

(Data available from 10/4/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)

KNTE Price Target - Frequently Asked Questions

What is Kinnate Biopharma's consensus rating and price target?: According to the issued ratings of 5 analysts in the last year, the consensus rating for Kinnate Biopharma stock is Buy based on the current 5 buy ratings for KNTE. The average twelve-month price prediction for Kinnate Biopharma is $32.00 with a high price target of $35.00 and a low price target of $29.00. Learn more on KNTE's analyst rating history.
Do Wall Street analysts like Kinnate Biopharma more than its competitors?: Analysts like Kinnate Biopharma more than other Medical companies. The consensus rating score for Kinnate Biopharma is 3.00 while the average consensus rating score for medical companies is 2.68. Learn more on how KNTE compares to other companies.
Do MarketBeat users like Kinnate Biopharma more than its competitors?: MarketBeat users like Kinnate Biopharma less than other Medical companies. 64.71% of MarketBeat users gave Kinnate Biopharma an outperform vote while medical companies recieve an average of 66.67% outperform votes by MarketBeat users.

Does Kinnate Biopharma's stock price have much upside?: According to analysts, Kinnate Biopharma's stock has a predicted upside of 191.97% based on their 12-month price targets.
What analysts cover Kinnate Biopharma?: Kinnate Biopharma has been rated by HC Wainwright, and Wedbush in the past 90 days.

Stock Ratings Reports and Tools

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

Ratings for Popular Stocks:

This page (NASDAQ:KNTE) was last updated on 10/4/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms